April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Rates of Change of Mean Deviation in the Ocular Hypertension Treatment Study
Author Affiliations & Notes
  • S. Demirel
    Devers Eye Institute, Legacy Health, Portland, Oregon
  • C. G. de Moraes
    Ophthalmology, New York Eye & Ear Infirmary, New York, New York
    Ophthalmology, NYU School of Medicine, New York, New York
  • S. K. Gardiner
    Devers Eye Institute, Legacy Health, Portland, Oregon
  • J. M. Liebmann
    Ophthalmology, New York Eye & Ear Infirmary, New York, New York
    Ophthalmology, NYU School of Medicine, New York, New York
  • G. A. Cioffi
    Devers Eye Institute, Legacy Health, Portland, Oregon
  • R. Ritch
    Ophthalmology, New York Eye & Ear Infirmary, New York, New York
  • M. O. Gordon
    Ophthal & Vis Sciences, Washington Univ Sch of Med, St Louis, Missouri
  • M. A. Kass
    Ophthal & Vis Sciences, Washington Univ Sch of Med, St Louis, Missouri
  • Ocular Hypertension Treatment Study
    Devers Eye Institute, Legacy Health, Portland, Oregon
  • Footnotes
    Commercial Relationships  S. Demirel, None; C.G. de Moraes, None; S.K. Gardiner, None; J.M. Liebmann, Diopsys, Inc., F; Heidelberg Engineering, GmbH, F; Optovue, Inc., F; Topcon Medical Systems, Inc., F; Reichert, F; Carl Zeiss Meditec, Inc., F; Alcon Laboratories, Inc., C; Allergan, Inc., C; Diopsys, Inc., C; Optovue, Inc., C; Pfizer Inc., C; Topcon Medical Systems, Inc., C; G.A. Cioffi, None; R. Ritch, Carl Zeiss Meditec, Inc., F; Diopsys, Inc., F; Heidelberg Engineering, GmBH., F; Topcon, Inc., F; Reichert, F; Alcon Laboratories, Inc., C; Allergan, Inc., C; Danube Pharmaceuticals, Inc., C; Pfizer Ophthalmics, Inc., C; M.O. Gordon, None; M.A. Kass, None.
  • Footnotes
    Support  NIH EY09307, EY09341; NCMHD; Merck; Pfizer; Research to Prevent Blindness; Gildor Research Fund; Glaucoma Research and Education fund of Lenox Hill Hospital; Legacy Good Samaritan Foundation.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 5520. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      S. Demirel, C. G. de Moraes, S. K. Gardiner, J. M. Liebmann, G. A. Cioffi, R. Ritch, M. O. Gordon, M. A. Kass, Ocular Hypertension Treatment Study; Rates of Change of Mean Deviation in the Ocular Hypertension Treatment Study. Invest. Ophthalmol. Vis. Sci. 2010;51(13):5520.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract
 
Purpose:
 

To assess the rates of change of visual field mean deviation (MD) in OHTS, overall, among eyes developing POAG and by how POAG was determined.

 
Methods:
 

The analysis dataset included eyes with ≥ 10 reliable visual fields (VF) covering ≥ 5 years; 2865 eyes from 1438 participants met these criteria. The rate of change of MD over time [MDR (dB/Yr)] was calculated for each eye using linear regression. Differences in MDR by POAG outcome and whether a POAG endpoint was detected for VF, optic disc or both VF and optic disc were tested using general estimating equations that took account of correlations between eyes of individuals.

 
Results:
 

The MDRs for different categories of eyes are shown below. The average MDR was significantly worse than zero for all eyes and for non-POAG eyes separately (both p < 0.001). POAG eyes had significantly worse MDRs than non-POAG eyes (C vs. B, p < 0.001). VF endpoint only eyes had significantly worse MDRs than non-POAG eyes (D vs. B, p < 0.001), as did optic disc endpoint only eyes (E vs. B, p = 0.024). Eyes that reached an optic disc and VF endpoint, not necessarily concurrently, deteriorated fastest, and significantly faster than VF endpoint only eyes (F vs. D, p = 0.004).

 
Conclusions:
 

Our analyses show that non-POAG ocular hypertensive eyes deteriorate significantly faster than established normative rates. Eyes that develop POAG show significantly worse MDRs than non-POAG eyes, regardless of endpoint type. Eyes that reach both an optic disc endpoint and a VF endpoint at any time during follow up had significantly worse MDRs than eyes that only reached a VF endpoint.  

 
Clinical Trial:
 

www.clinicaltrials.gov NCT00000125

 
Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled clinical trials • visual fields • optic disc 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×